Alterations of lymphoid enhancer factor-1 isoform expression in solid tumors and acute leukemias

Wenbing Wang, Ping Ji, Björn Steffen, Ralf Metzger, Paul M. Schneider, Hartmut Halfter, Mark Schrader, Wolfgang E. Berdel, Hubert Serve, Carsten Müller-Tidow

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Two major transcripts of lymphoid enhancer factor-1 (LEF-1) have been described. The long isoform with β-catenin binding domain functions as a transcriptional enhancer factor. The short isoform derives from an intronic promoter and exhibits dominant negative activity. Recently, alterations of LEF-1 isoforms distribution have been described in colon cancer. In the current study we employed a quantitative real-time reverse transcription PCR method (TaqMan) to analyze expression of LEF-1 isoforms in a large cohort of human tumor (n=304) and tumor-free control samples (n=56). The highest expression level of LEF-1 was found in carcinoma samples whereas brain cancer samples expressed little. Expression of LEF-1 was different in distinct cancer types. For example, the mRNA level of LEF-1 was lower in testicular tumor samples compared with tumor-free control samples. Besides epithelial cancers, significant LEF-1 expression was also found in hematopoietic cells. In hematological malignancies, overall LEF-1 level was higher in lymphocytic leukemias compared with myeloid leukemias and normal hematopoiesis. However, acute myeloid leukemia and acute lymphocytic leukemia showed a significantly increased fraction of the oncogenic LEF-1 compared with chronic lymphocytic leukemia and chronic myeloid leukemia. Taken together, these data suggest that LEF-1 is abundantly expressed in human tumors and the ratio of the oncogenic and the dominant negative short isoform altered not only in carcinomas but also in leukemia.

Original languageEnglish (US)
Pages (from-to)173-180
Number of pages8
JournalActa Biochimica et Biophysica Sinica
Volume37
Issue number3
StatePublished - Mar 2005
Externally publishedYes

Fingerprint

TCF Transcription Factors
Tumors
Protein Isoforms
Leukemia
Neoplasms
Carcinoma
Lymphoid Leukemia
Catenins
Myeloid Leukemia
Testicular Neoplasms
Hematopoiesis
Hematologic Neoplasms
B-Cell Chronic Lymphocytic Leukemia
Transcription
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Brain Neoplasms
Colonic Neoplasms
Reverse Transcription

Keywords

  • β-catenin
  • AML
  • Isoform
  • Lymphoid enhancer factor (LEF-1)
  • Solid tumor

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics

Cite this

Wang, W., Ji, P., Steffen, B., Metzger, R., Schneider, P. M., Halfter, H., ... Müller-Tidow, C. (2005). Alterations of lymphoid enhancer factor-1 isoform expression in solid tumors and acute leukemias. Acta Biochimica et Biophysica Sinica, 37(3), 173-180.

Alterations of lymphoid enhancer factor-1 isoform expression in solid tumors and acute leukemias. / Wang, Wenbing; Ji, Ping; Steffen, Björn; Metzger, Ralf; Schneider, Paul M.; Halfter, Hartmut; Schrader, Mark; Berdel, Wolfgang E.; Serve, Hubert; Müller-Tidow, Carsten.

In: Acta Biochimica et Biophysica Sinica, Vol. 37, No. 3, 03.2005, p. 173-180.

Research output: Contribution to journalArticle

Wang, W, Ji, P, Steffen, B, Metzger, R, Schneider, PM, Halfter, H, Schrader, M, Berdel, WE, Serve, H & Müller-Tidow, C 2005, 'Alterations of lymphoid enhancer factor-1 isoform expression in solid tumors and acute leukemias', Acta Biochimica et Biophysica Sinica, vol. 37, no. 3, pp. 173-180.
Wang, Wenbing ; Ji, Ping ; Steffen, Björn ; Metzger, Ralf ; Schneider, Paul M. ; Halfter, Hartmut ; Schrader, Mark ; Berdel, Wolfgang E. ; Serve, Hubert ; Müller-Tidow, Carsten. / Alterations of lymphoid enhancer factor-1 isoform expression in solid tumors and acute leukemias. In: Acta Biochimica et Biophysica Sinica. 2005 ; Vol. 37, No. 3. pp. 173-180.
@article{49e88e733187446fab115d5fd745fa5d,
title = "Alterations of lymphoid enhancer factor-1 isoform expression in solid tumors and acute leukemias",
abstract = "Two major transcripts of lymphoid enhancer factor-1 (LEF-1) have been described. The long isoform with β-catenin binding domain functions as a transcriptional enhancer factor. The short isoform derives from an intronic promoter and exhibits dominant negative activity. Recently, alterations of LEF-1 isoforms distribution have been described in colon cancer. In the current study we employed a quantitative real-time reverse transcription PCR method (TaqMan) to analyze expression of LEF-1 isoforms in a large cohort of human tumor (n=304) and tumor-free control samples (n=56). The highest expression level of LEF-1 was found in carcinoma samples whereas brain cancer samples expressed little. Expression of LEF-1 was different in distinct cancer types. For example, the mRNA level of LEF-1 was lower in testicular tumor samples compared with tumor-free control samples. Besides epithelial cancers, significant LEF-1 expression was also found in hematopoietic cells. In hematological malignancies, overall LEF-1 level was higher in lymphocytic leukemias compared with myeloid leukemias and normal hematopoiesis. However, acute myeloid leukemia and acute lymphocytic leukemia showed a significantly increased fraction of the oncogenic LEF-1 compared with chronic lymphocytic leukemia and chronic myeloid leukemia. Taken together, these data suggest that LEF-1 is abundantly expressed in human tumors and the ratio of the oncogenic and the dominant negative short isoform altered not only in carcinomas but also in leukemia.",
keywords = "β-catenin, AML, Isoform, Lymphoid enhancer factor (LEF-1), Solid tumor",
author = "Wenbing Wang and Ping Ji and Bj{\"o}rn Steffen and Ralf Metzger and Schneider, {Paul M.} and Hartmut Halfter and Mark Schrader and Berdel, {Wolfgang E.} and Hubert Serve and Carsten M{\"u}ller-Tidow",
year = "2005",
month = "3",
language = "English (US)",
volume = "37",
pages = "173--180",
journal = "Sheng wu hua xue yu sheng wu wu li xue bao Acta biochimica et biophysica Sinica",
issn = "1672-9145",
publisher = "Shanghai Kexue Jishu Chubanshe/Shanghai Scientific & Technical Publishers",
number = "3",

}

TY - JOUR

T1 - Alterations of lymphoid enhancer factor-1 isoform expression in solid tumors and acute leukemias

AU - Wang, Wenbing

AU - Ji, Ping

AU - Steffen, Björn

AU - Metzger, Ralf

AU - Schneider, Paul M.

AU - Halfter, Hartmut

AU - Schrader, Mark

AU - Berdel, Wolfgang E.

AU - Serve, Hubert

AU - Müller-Tidow, Carsten

PY - 2005/3

Y1 - 2005/3

N2 - Two major transcripts of lymphoid enhancer factor-1 (LEF-1) have been described. The long isoform with β-catenin binding domain functions as a transcriptional enhancer factor. The short isoform derives from an intronic promoter and exhibits dominant negative activity. Recently, alterations of LEF-1 isoforms distribution have been described in colon cancer. In the current study we employed a quantitative real-time reverse transcription PCR method (TaqMan) to analyze expression of LEF-1 isoforms in a large cohort of human tumor (n=304) and tumor-free control samples (n=56). The highest expression level of LEF-1 was found in carcinoma samples whereas brain cancer samples expressed little. Expression of LEF-1 was different in distinct cancer types. For example, the mRNA level of LEF-1 was lower in testicular tumor samples compared with tumor-free control samples. Besides epithelial cancers, significant LEF-1 expression was also found in hematopoietic cells. In hematological malignancies, overall LEF-1 level was higher in lymphocytic leukemias compared with myeloid leukemias and normal hematopoiesis. However, acute myeloid leukemia and acute lymphocytic leukemia showed a significantly increased fraction of the oncogenic LEF-1 compared with chronic lymphocytic leukemia and chronic myeloid leukemia. Taken together, these data suggest that LEF-1 is abundantly expressed in human tumors and the ratio of the oncogenic and the dominant negative short isoform altered not only in carcinomas but also in leukemia.

AB - Two major transcripts of lymphoid enhancer factor-1 (LEF-1) have been described. The long isoform with β-catenin binding domain functions as a transcriptional enhancer factor. The short isoform derives from an intronic promoter and exhibits dominant negative activity. Recently, alterations of LEF-1 isoforms distribution have been described in colon cancer. In the current study we employed a quantitative real-time reverse transcription PCR method (TaqMan) to analyze expression of LEF-1 isoforms in a large cohort of human tumor (n=304) and tumor-free control samples (n=56). The highest expression level of LEF-1 was found in carcinoma samples whereas brain cancer samples expressed little. Expression of LEF-1 was different in distinct cancer types. For example, the mRNA level of LEF-1 was lower in testicular tumor samples compared with tumor-free control samples. Besides epithelial cancers, significant LEF-1 expression was also found in hematopoietic cells. In hematological malignancies, overall LEF-1 level was higher in lymphocytic leukemias compared with myeloid leukemias and normal hematopoiesis. However, acute myeloid leukemia and acute lymphocytic leukemia showed a significantly increased fraction of the oncogenic LEF-1 compared with chronic lymphocytic leukemia and chronic myeloid leukemia. Taken together, these data suggest that LEF-1 is abundantly expressed in human tumors and the ratio of the oncogenic and the dominant negative short isoform altered not only in carcinomas but also in leukemia.

KW - β-catenin

KW - AML

KW - Isoform

KW - Lymphoid enhancer factor (LEF-1)

KW - Solid tumor

UR - http://www.scopus.com/inward/record.url?scp=21144435076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21144435076&partnerID=8YFLogxK

M3 - Article

VL - 37

SP - 173

EP - 180

JO - Sheng wu hua xue yu sheng wu wu li xue bao Acta biochimica et biophysica Sinica

JF - Sheng wu hua xue yu sheng wu wu li xue bao Acta biochimica et biophysica Sinica

SN - 1672-9145

IS - 3

ER -